9th Jan 2025 11:21
ImmuPharma PLC - London-based specialist drug discovery and development company - Says its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases has yielded data that provides novel insights into autoimmune mechanisms. P140, the firms lead programme, is a unique non-immunosuppressive peptide for the treatment of systemic lupus erythematosus and chronic idiopathic demyelinating polyneuropathy. Adds that the findings, which were discovered by its R&D subsidiary ImmuPharma Biotech, pave the way for better diagnostics, identifying patients most likely to respond to P140 therapy and improved patient monitoring. Says the research marks a "significant step towards personalised medicine in SLE and other autoimmune diseases." Details of the data findings are not being released at this time since they form part of the ongoing expansion of the firms intellectual property portfolio. Read More